SCHEMBL2117419

SCHEMBL2117419

COc1ccc(S(=O)(=O)Nc2cc(-c3ccc(C)s3)ccc2C)nc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.42
USP8 P40818 1/20 0.42
GHSR Q92847 2/20 0.41
MAPT P10636 2/20 0.41
ALDH1A1 P00352 3/20 0.40
CYP2C9 P11712 1/20 0.40
TSHR P16473 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
KDM4E B2RXH2 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
KEAP1 Q14145 1/20 0.38
GLO1 Q04760 1/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
PIK3CG P48736 1/20 0.37
PRF1 P14222 2/20 0.37
AKT1 P31749 1/20 0.37
PIK3CA P42336 1/20 0.37
MTOR P42345 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2117835 0.88 MAPT (0.39) USP2USP8GHSRMAPTALDH1A1
SCHEMBL2117520 0.85 MAPT (0.39) GHSRMAPTALDH1A1CYP2C9TSHR
SCHEMBL2118512 0.85 GHSR (0.45) GHSRMAPTALDH1A1CYP2C9TSHR
SCHEMBL2117725 0.85 GHSR (0.41) GHSRMAPTALDH1A1CYP2C9TSHR
SCHEMBL2120887 0.85 ALDH1A1 (0.40) USP2USP8GHSRMAPTALDH1A1
SCHEMBL2118122 0.84 MAPT (0.48) GHSRMAPTALDH1A1CYP2C9TSHR
SCHEMBL2118535 0.80 MAPT (0.43) USP2USP8GHSRMAPTALDH1A1
SCHEMBL2120234 0.80 PRF1 (0.51) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL2119029 0.80 ACLY (0.49) MAPTALDH1A1CYP2C9TSHRNPSR1
SCHEMBL2116789 0.80 GHSR (0.53) GHSRMAPTALDH1A1CYP2C9TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1A, HIF1AN, EGLN3 USP2 2494/4885USP8 3487/4885GHSR 1390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.